US Patent Issued to Oxford Drug Design on March 11 for "2-amino-N-(amino-oxo-aryl-lambda 6 -sulfanylidene)acetamide compounds and their therapeutic use" (British, Latvian Inventors)

ALEXANDRIA, Va., March 12 -- United States Patent no. 12,247,004, issued on March 11, was assigned to Oxford Drug Design Ltd. (London).

"2-amino-N-(amino-oxo-aryl-lambda 6 -sulfanylidene)acetamide compounds and their therapeutic use" was invented by Grace Edmund (London), Michael H. Charlton (Oxford, Great Britain), Paul William Finn (Faringdon, Great Britain), Aigars Jirgensons (Riga, Latvia), Marija Skvorcova (Riga, Latvia), Janis Veliks (Riga, Latvia) and Liene Grigorjeva (Riga, Latvia).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-Lambda6-su...